ES2566033T3 - Parvovirus recombinante atenuado - Google Patents

Parvovirus recombinante atenuado Download PDF

Info

Publication number
ES2566033T3
ES2566033T3 ES11706253.9T ES11706253T ES2566033T3 ES 2566033 T3 ES2566033 T3 ES 2566033T3 ES 11706253 T ES11706253 T ES 11706253T ES 2566033 T3 ES2566033 T3 ES 2566033T3
Authority
ES
Spain
Prior art keywords
attenuated recombinant
recombinant parvovirus
attenuated
parvovirus
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11706253.9T
Other languages
English (en)
Spanish (es)
Inventor
Norman Spibey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Application granted granted Critical
Publication of ES2566033T3 publication Critical patent/ES2566033T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14361—Methods of inactivation or attenuation
    • C12N2750/14362—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES11706253.9T 2010-03-05 2011-03-03 Parvovirus recombinante atenuado Active ES2566033T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31103210P 2010-03-05 2010-03-05
US311032P 2010-03-05
EP10155646 2010-03-05
EP10155646 2010-03-05
PCT/EP2011/053164 WO2011107534A1 (en) 2010-03-05 2011-03-03 Recombinant attenuated parvovirus

Publications (1)

Publication Number Publication Date
ES2566033T3 true ES2566033T3 (es) 2016-04-08

Family

ID=42562704

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11706253.9T Active ES2566033T3 (es) 2010-03-05 2011-03-03 Parvovirus recombinante atenuado

Country Status (10)

Country Link
US (1) US9234182B2 (cg-RX-API-DMAC7.html)
EP (1) EP2542260B1 (cg-RX-API-DMAC7.html)
JP (3) JP6200155B2 (cg-RX-API-DMAC7.html)
CN (1) CN102791288B (cg-RX-API-DMAC7.html)
AU (1) AU2011222910B2 (cg-RX-API-DMAC7.html)
CA (1) CA2790653C (cg-RX-API-DMAC7.html)
DK (1) DK2542260T3 (cg-RX-API-DMAC7.html)
ES (1) ES2566033T3 (cg-RX-API-DMAC7.html)
RU (1) RU2527157C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011107534A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9234182B2 (en) * 2010-03-05 2016-01-12 Intervet Inc. Recombinant attenuated parvovirus
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US20140234354A1 (en) * 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CN105263953B (zh) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 猪细小病毒5a、使用方法及疫苗
BR112016023787A2 (pt) 2014-04-17 2017-10-17 Intervet Int Bv vírus isolado, cultura de células, fragmento de dna, proteína do capsídeo, gene ns1, vacina para combater parvovírus suíno associado com hbs em suínos, anticorpo ou antissoro, método para a preparação de uma vacina, e, kits de teste diagnóstico para a detecção de anticorpos reativos com um vírus e de um vírus
KR102664662B1 (ko) 2016-11-03 2024-05-14 베링거잉겔하임베트메디카게엠베하 돼지 파보바이러스 및 돼지 생식기 및 호흡기 증후군 바이러스에 대한 백신 및 이의 제조 방법
TWI781962B (zh) 2016-11-03 2022-11-01 德商百靈佳殷格翰維美迪加股份有限公司 抗豬小病毒疫苗
WO2022096472A1 (en) 2020-11-04 2022-05-12 Intervet International B.V. Canine parvovirus
CN114957406B (zh) * 2022-05-26 2024-02-02 吉林大学 一种犬细小病毒的三价抗原和三价病毒样颗粒以及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8502399D0 (en) * 1985-01-31 1985-03-06 Akzo Nv Canine parvovirus vaccines
JP2002538770A (ja) * 1998-11-10 2002-11-19 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ウイルスベクターとその製造及び投与の方法
EP2292250A1 (en) * 2005-07-28 2011-03-09 Pfizer Products Inc. Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline parvovirus and feline herpes virus
EP2170383A4 (en) * 2007-06-14 2012-12-26 Univ Oklahoma State GENETIC VARIANTS OF DOG PARVOVIRUS CONTAINING VACCINES
US9234182B2 (en) * 2010-03-05 2016-01-12 Intervet Inc. Recombinant attenuated parvovirus

Also Published As

Publication number Publication date
US20120328652A1 (en) 2012-12-27
CA2790653A1 (en) 2011-09-09
DK2542260T3 (en) 2016-06-06
JP6346143B2 (ja) 2018-06-20
US9234182B2 (en) 2016-01-12
JP2018134088A (ja) 2018-08-30
CN102791288A (zh) 2012-11-21
BR112012021650A2 (pt) 2017-02-21
AU2011222910B2 (en) 2014-09-18
JP6200155B2 (ja) 2017-09-20
EP2542260A1 (en) 2013-01-09
RU2012142309A (ru) 2014-04-10
EP2542260B1 (en) 2016-03-02
CN102791288B (zh) 2015-02-18
RU2527157C2 (ru) 2014-08-27
AU2011222910A1 (en) 2012-09-27
CA2790653C (en) 2019-02-19
WO2011107534A1 (en) 2011-09-09
JP2016047053A (ja) 2016-04-07
JP2013520977A (ja) 2013-06-10

Similar Documents

Publication Publication Date Title
ES2566033T3 (es) Parvovirus recombinante atenuado
ES2569365T3 (es) Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
CL2009000190A1 (es) Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molecula de adn que codifica el genoma y/o antigenoma del virus; celula y composicion que lo comprenden.
ES2683695T3 (es) Repeticiones terminales invertidas restrictivas para vectores virales
CL2012001068A1 (es) Polinucleotido que codifica oleosina modificada incluyendo al menos una cisteina introducida artificialmente, constructo genetico que comprende dicho polinucleotido; célula huesped; composicion que comprende un cuerpo oleoso; alimento animal que comprende el cuerpo oleoso.
CL2012002969A1 (es) Vector viral adenoasociado recombinante (raav) que comprende promotor de rodopsina quinasa humana especifica del fotorreceptor, o promotor de beta-actina de pollo cmv quimerico truncado ubicuo unido a al menos un adn que codifica una guanilato ciclasa; virion o particula viral infecciosa que comprende el vector; celula huesped; composicion que comprende el vector.
AR079882A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
AR079881A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
MX377804B (es) Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
ECSP15011603A (es) Subunidades de vacunas de inmersión para peces
EP3795581A3 (en) New avv capsid proteins for nucleic acid transfer
CO6290791A2 (es) Vacunas y composiciones inmunogénicas que contienen nuevas cepas del circo virus porcino tipo 2b para inmunizar cerdos contra pmws
MX385620B (es) Transferencia de genes al sistema nervioso central mediada por virus adeno-asociados.
AR079972A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
JP2013510581A5 (cg-RX-API-DMAC7.html)
EA201070066A1 (ru) Вакцины против гриппа с низким содержанием добавок
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
EA201001045A1 (ru) Модифицированный вирус гриппа
BR112012003837B8 (pt) Vacina de paramyxovírus aviária recombinante e método para fazer e usar a mesma
PH12013500925B1 (en) North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
BRPI0919696A2 (pt) Polipeptídeo substancialmente purificado, microorganismo recombinante, e, polinucleotídeo isolado.
CL2011002913A1 (es) Plasmido novedoso con numero de acceso mtcc 5561; virus de vaccinia ankara modificado (mva) recombinante.
CL2012002900A1 (es) Secuencias de acido nucleico procedente de un virus causante del sindrome de miocardiopatia (cms) en peces; vector; celula huesped; vacuna de adn; proteina recombinante codificada; vacuna recombinante; inmunoensayo para la deteccion de dicho virus; kit de diagnostico; y uso de las mismas.